Mitralign added more than $8 million to its coffers in an equity funding round, after closing enrollment of a clinical trial for its namesake mitral valve repair device in April.
The Mitralign system is designed to deliver via catheter at least 1 pair of anchors that, when cinched together, help restore the heart’s mitral valve to its natural shape in patients with functional mitral regurgitation, according to a press release.
Tewksbury, Mass.-based Mitralign, which landed a $35 million Series D round in May 2012, reported raising about $8.1 million from 12 unnamed investors, including 3 backers from outside the U.S.
In April, Mitralign said it had completed enrollment in a clinical trial of the eponymous device it plans to use to back an application for CE Mark approval in the European Union.
“This is an important milestone for our company and brings our Mitralign System that much closer to patients who suffer this severe heart disease,” CEO Rick Geoffrion said in prepared remarks. “We have completed the enrollment of 61 FMR patients in Europe, and we are in the process of collecting the necessary follow-up data for submission to our notified body in Europe for CE Mark approval. In the meantime, we will continue to enroll patients within our active clinical studies in order to accrue additional data for the medical community. We expect to report results from this trial before the end of 2014.”